News

Categories

November 18, 2025

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

November 18, 2025

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

November 17, 2025

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

November 6, 2025

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

October 28, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

October 23, 2025

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

October 16, 2025

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

October 13, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

October 9, 2025

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

September 2, 2025

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

August 19, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

August 11, 2025

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry